Active Biotech Year-End Report 2006


Positive Results for All Five Clinical Projects in 2006

  • New share issue totaling SEK 240 M oversubscribed by 53%
  • Call for premature repayment of convertible debenture loan
    (see separate press release)
  • Net sales SEK 66.4 M (9.2)
  • Operating loss SEK 124.6 M (loss: 133.2)
  • Loss after tax SEK 139.2 M (Loss: 135.4)
  • Loss per share for the period amounted to SEK 3.50 (3.70)
  • Comments from President and CEO Sven Andréasson:
    "2006 was another successful year for our projects. All five projects in clinical phases proceeded according to defined milestones. In 2007, Active Biotech will have one project in Phase III, four projects in Phase II and a new project in Phase I. Our projects are now well advanced and the diversification of risks in the project portfolio has been significantly improved."
    "Our recently implemented new share issue provides the company with a capital injection that enables the continued development of the our extensive clinical portfolio. In 2007, the projects will enter larger, more capital-intensive development phases. The preclinical activities will also increase in the next few years. We now have a solid base from which we can execute these programs."

    For further information, please contact:
    Sven Andréasson Cecilia Hofvander
    President and CEO Manager Corporate Communications
    Tel: +46 (0)46-19 20 49 Tel: +46 (0)46-19 11 22
    Active Biotech AB (Corp. Reg. No. 556223-9227)
    PO Box 724
    SE-220 07 Lund
    Tel. +46 (0)46-19 20 00
    Fax +46 (0)46-19 20 50 This report is also available at

    pdfActive Biotech Year-End Report 2006